Filing Flows › Tvardi Therapeutics (TVRD) › Q4 2024
Tvardi Therapeutics (TVRD) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Tvardi Therapeutics (TVRD) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), -52% from a year earlier and -43% from the quarter before. Operating margin was -372.7%, net loss $7.7M (527.8% of revenue).
Tvardi Therapeutics, Q4 2024: revenue $1.5M (-52% year over year), operating margin -372.7%, net loss $7.7M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -43% | -52% |
| Operating profit | −$5.4M | — | — |
| Net earnings | −$7.7M | — | — |
| Operating cash flow | −$4.0M | — | — |
What changed
Revenue was $1.5M in Q4 2024, down 52% year over year and down 43% from the previous quarter.
Operating costs exceeded revenue by $5.4M, an operating margin of -372.7%. Total costs fell 81% while revenue fell 52%. The quarter ended with a net loss of $7.7M, narrower than the previous quarter's $12.5M loss.
Operating cash flow was −$4.0M. Non-cash charges added back $2.4M of share-based compensation. Working capital and other items added $1.3M.
Questions
What was Tvardi Therapeutics' revenue in the fourth quarter 2024?
Tvardi Therapeutics (TVRD) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), -52% from a year earlier and -43% from the quarter before.
Was Tvardi Therapeutics profitable in the fourth quarter 2024?
Operating loss was $5.4M (-372.7% of revenue) and net loss $7.7M.